AdipoPharma

Company profile

AdipoPharma company profile

AdipoPharma is a clinical stage biotech company developing PATAS a first-in-class whole-body insulin sensitizing therapeutic to treat Insulin resistance the primary cause of Type 2 Diabetes. Type 2 diabetes is the fastest chronic growing disease on the planet and is projected to globally effect over 1.3 billion people within the next 20 years. The worldwide silent growing insulin market (estimated to reach 100 billion by 2035) is a testament to the failure of the current anti-diabetic therapeutics currently available on the market. Cardiovascular disease, fatty liver disease, chronic kidney disease, blindness and neuropathy are its devastating complications resulting in enormous costs estimated to be + $450 Billion in the US alone.